H-Phg(4-OH)-OH
(Synonyms: L-(+)-对羟基苯甘氨酸,L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842) 目录号 : GC38272A CPT1 inhibitor and prodrug form of 4-hydroxyphenylglyoxylic acid
Cas No.:32462-30-9
Sample solution is provided at 25 µL, 10mM.
Oxfenicine is an inhibitor of carnitine palmitoyltransferase 1 (CPT1) and a prodrug form of 4-hydroxyphenylglyoxylic acid.1,2 Oxfenicine is transaminated to 4-hydroxyphenylglyoxylic acid by branched-chain amino acid aminotransferase in rat heart homogenates.3 It inhibits fatty acid oxidation and increases carbohydrate oxidation in isolated rat hearts perfused with palmitate , glucose, and insulin.4 Oxfenicine increases the ex vivo activity of cardiac pyruvate dehydrogenase (PDH) in rats with an ED50 value of 0.3 mmol/kg.1 It reduces increases in plasma levels of lactate and lactate dehydrogenase 1 (LDH-1), markers of ischemic injury, in a dog model of microsphere-induced coronary ischemia when administered at a dose of 0.1 mmol/kg.5
1.Barnish, I.T., Cross, P.E., Danilewicz, J.C., et al.Promotion of carbohydrate oxidation in the heart by some phenylglyoxylic acidsJ. Med. Chem.24(4)399-404(1981) 2.Bielefeld, D.R., Vary, T.C., and Neely, J.R.Inhibition of carnitine palmitoyl-CoA transferase activity and fatty acid oxidation by lactate and oxfenicine in cardiac muscleJ. Mol. Cell. Cardiol.17(6)619-625(1985) 3.Higgins, A.J., Morville, M., Burges, R.A., et al.Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate oxidation and protects the ischaemic rat heartLife Sci.27(11)963-970(1980) 4.Burges, R.A., Gardiner, D.G., and Higgins, A.J.Protection of the ischaemic dog heart by oxfenicineLife Sci.29(18)1847-1853(1981)
Cas No. | 32462-30-9 | SDF | |
别名 | L-(+)-对羟基苯甘氨酸,L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842 | ||
Canonical SMILES | O=C(O)[C@@H](N)C1=CC=C(O)C=C1 | ||
分子式 | C8H9NO3 | 分子量 | 167.16 |
溶解度 | H2O : 4.55 mg/mL (27.22 mM; Need ultrasonic); DMSO : < 1 mg/mL (insoluble or slightly soluble) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 5.9823 mL | 29.9115 mL | 59.8229 mL |
5 mM | 1.1965 mL | 5.9823 mL | 11.9646 mL |
10 mM | 0.5982 mL | 2.9911 mL | 5.9823 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet